/IPSC
IPSC Stock - Century Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.90+17.89%
+$0.14 (+17.89%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.48
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1733.3%upside
Target: $16.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IPSC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.89 – $0.91
TARGET (TP)$16.50
STOP LOSS$0.83
RISK/REWARD1:222.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.81
52W High$1.19
52W Low$0.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $6.59M | $2.23M | $5.20M | N/A | N/A |
| Gross Profit | $6.59M | $2.23M | $5.20M | $-4,582,000 | $-1,754,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | N/A | N/A |
| Operating Income | $-138,137,000 | $-146,546,000 | $-133,831,000 | $-94,883,000 | $-49,176,000 |
| Net Income | $-126,566,000 | $-136,673,000 | $-130,932,000 | $-95,824,000 | $-53,575,000 |
| Net Margin | -1920.9% | -6115.1% | -2518.4% | N/A | N/A |
| EPS | $-1.61 | $-2.30 | $-2.27 | $-1.74 | $-1.00 |
Company Overview
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$17
Average Target
↑ 1751.9% Upside
Now
$5
Low
$17
Average
$28
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 8th 2024 | Rodman & Renshaw | Initiation | Buy | $6 |
| August 28th 2023 | JP Morgan | Downgrade | Neutral | $5← $28 |
| December 27th 2022 | Chardan Capital Markets | Initiation | Buy | $19 |
| October 31st 2022 | Guggenheim | Initiation | Buy | $15 |
| October 10th 2022 | Canaccord Genuity | Initiation | Buy | $28 |
| May 23rd 2022 | H.C. Wainwright | Initiation | Buy | $27 |
| May 12th 2022 | William Blair | Initiation | Market Perform | - |
Earnings History & Surprises
IPSCBeat Rate
56%
Last 18 quarters
Avg Surprise
+5.5%
EPS vs Estimate
Beats / Misses
10/6
2 met exactly
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q1 24
+12.5%
$-0.49vs$-0.56
Q2 24
+10.0%
$-0.45vs$-0.50
Q3 24
+24.0%
$-0.38vs$-0.50
Q4 24
+19.6%
$-0.37vs$-0.46
Q1 25
+4.4%
$-0.43vs$-0.45
Q2 25
+387.1%
$0.89vs$-0.31
Q3 25
0.0%
$-0.38vs$-0.38
Q4 25
+17.9%
$-0.32vs$-0.39
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 18, 2026 | $-0.29 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.39 | $-0.32 | +17.9% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.38 | $-0.38 | 0.0% | = MET |
Q2 2025 | May 15, 2025 | $-0.31 | $0.89 | +387.1% | ✓ BEAT |
Q1 2025 | Mar 19, 2025 | $-0.45 | $-0.43 | +4.4% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-0.46 | $-0.37 | +19.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.50 | $-0.38 | +24.0% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.50 | $-0.45 | +10.0% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.56 | $-0.49 | +12.5% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.53 | $-0.55 | -3.8% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.54 | $-0.56 | -3.7% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.53 | $-0.53 | 0.0% | = MET |
Q1 2023 | Mar 16, 2023 | $-0.59 | $-0.55 | +6.8% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.59 | $-0.53 | +10.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.50 | $-0.54 | -8.0% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.45 | $-0.66 | -46.7% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.46 | $-0.24 | +47.8% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.40 | $-0.48 | -20.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.42 | $-1.93 | -359.5% | ✗ MISS |
Q2 2021 | Jun 21, 2021 | — | $-0.37 | — | — |
Latest News
Leerink Partners Downgrades Century Therapeutics to Market Perform, Lowers Price Target to $2
📉 NegativeBenzinga•Nov 17, 2025, 12:29 PM
Century Therapeutics Q3 EPS $(0.40) Misses $(0.34) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 12:34 PM
Century Therapeutics Launches Allo-Evasion 5.0 Ipsc Beta Islet Program For Type 1 Diabetes With Preclinical Data Showing Rapid Diabetes Reversal And Plans Ind-Enabling Studies By Year-End 2025
📈 PositiveBenzinga•Nov 13, 2025, 12:26 PM
Frequently Asked Questions about IPSC
What is IPSC's current stock price?
Century Therapeutics, Inc. (IPSC) is currently trading at $0.90 per share. The stock has moved +17.89% today.
What is the analyst price target for IPSC?
The average analyst price target for IPSC is $16.50, based on 1 analyst.
What sector is Century Therapeutics, Inc. in?
Century Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IPSC's market cap?
Century Therapeutics, Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does IPSC pay dividends?
No, Century Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
EQ
Equillium, Inc.
$1.15
Mkt Cap: $0.0B
GNTA
Genenta Science S.p.A.
$1.45
Mkt Cap: $0.0B
KPTI
Karyopharm Therapeutics Inc.
$6.94
Mkt Cap: $0.1B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
SNTI
Senti Biosciences, Inc.
$1.20
Mkt Cap: $0.0B
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$1.41
Mkt Cap: $0.0B
Explore stocks similar to IPSC for comparison